CKM Syndrome - Nephrology Lectures 2025

What CKM syndrome actually claims. Obesity, dysglycemia, chronic kidney disease and cardiovascular disease are not four illnesses that happen to co-occur. They are one pathophysiologic continuum with shared mediators and shared therapeutic targets — and a patient's position along that continuum predicts absolute cardiovascular risk better than counting discrete risk factors.

Visual reference

CKM, CKD Staging, and Kidney Failure Risk visual summary. Open for the full image and text version. — CKM, CKD Staging, and Kidney Failure Risk: full graphic and text version

Browse the visual reference library · Download lesson Markdown

📋 Why the 2026 guideline matters

The staging construct began as the 2023 AHA presidential advisory. The 2026 AHA/ACC/ADA/ASN guideline converts that advisory into a graded clinical practice guideline with formal COR/LOE recommendations, extends it across the life course, and retires and replaces the 2013 AHA/ACC/TOS obesity guideline.

For nephrology, one structural fact outranks the rest. ASN is a full endorsing society alongside ADA and the Obesity Association. CKD is not a downstream complication in this framework — it is a staging axis of equal standing with adiposity and dysglycemia, and very-high-risk CKD is treated as a cardiovascular risk equivalent in its own right. Nephrology is embedded in the framework rather than consulted by it.

🎯 The five stages at a glance

Stage 0No CKM syndrome. Normal weight, glucose, BP, lipids and kidney function; no subclinical or clinical CVD. Primordial prevention.

Stage 1Excess or dysfunctional adiposity, and/or prediabetes. No other metabolic risk factors, no CKD, no CVD.

Stage 2Metabolic risk factors and/or CKD — type 2 diabetes, hypertension, hypertriglyceridemia, metabolic syndrome, moderate-to-high-risk CKD.

Stage 3Subclinical CVD, or a CKM risk equivalent — very-high-risk CKD, or 10-year PREVENT-CVD risk at or above 20%.

Stage 4Clinical CVD. Substaged 4a (no kidney failure) and 4b (eGFR below 15 or chronic kidney replacement therapy).

Stage 4 is not "any coronary disease." A coronary calcium score of 900 without events is stage 3. A prior PCI is stage 4 even in a currently asymptomatic patient. The line is clinical events or revascularization — not atherosclerotic burden. Symptomatic heart failure at any ejection fraction qualifies, as does atrial fibrillation on its own, with no ischemic or structural disease required.

🧠 The one-sentence version

CKM staging answers "how aggressively do I treat cardiovascular risk, and with which agents?" It does not answer "how fast will this kidney fail?" Conflating the two is the most common misuse of the framework — and it is why the CKM versus KFRE deep dive exists.

📈 PREVENT — the risk engine underneath

PREVENT estimates 10- and 30-year risk of ASCVD, heart failure and total CVD, and takes eGFR and optionally UACR and HbA1c directly as inputs. It is recommended in stages 0–3; in stage 4 the patient already has clinical disease and prediction is superseded by secondary prevention.

Threshold	Action
PREVENT-CVD 10-year at or above 7.5%	Prioritize pharmacotherapy
PREVENT-CVD 10-year at or above 20%	Meets a stage 3 criterion as a risk equivalent
PREVENT-HF 10-year at or above 5% in prediabetes or T2D	Obtain natriuretic peptide with or without hs-troponin; image if elevated

💊 Therapy by stage

Stage	Architecture
1	Lifestyle as the foundation; obesity pharmacotherapy and metabolic/bariatric surgery as adjuncts, explicitly framed as tools to prevent progression and promote stage regression. First guideline to endorse GLP-1-based therapy for cardiovascular event reduction in selected patients with obesity, with or without T2D.
2	Metabolic: GLP-1-based agent or SGLT2 inhibitor with proven benefit when PREVENT-CVD is at or above 7.5%, or age over 50 with added risk factors. Metformin is adjunctive — layered onto cardioprotective agents rather than preceding them. Kidney: measure eGFR and UACR; RASi plus SGLT2i first-line.
3	Same architecture, intensified. Combination SGLT2i plus GLP-1-based therapy may be considered. Very-high-risk CKD alone qualifies — treat it as a CVD risk equivalent, not a kidney problem awaiting a cardiac indication.
4	ASCVD plus T2D: at least one agent with proven CV benefit in all patients. HFrEF: RASi (ARNI preferred), beta blocker, steroidal MRA, SGLT2i. HFmrEF/HFpEF: SGLT2i first-line. Obesity and kidney-protective therapy continue in parallel.

Persistent albuminuria on first-line therapy

Add-on	Threshold	Favored when
Finerenone	UACR at or above 30 mg/g	Normokalemic, albuminuria-predominant phenotype
Semaglutide	UACR at or above 100 mg/g	Obesity, uncontrolled diabetes, or MASLD present

SGLT2i is the first-line cardioprotective antihyperglycemic in T2D with heart failure or CKD, and is initiable down to eGFR 20 mL/min/1.73 m².

📚 Deep dives

🧬 Staging and the kidney axis ⚖️ CKM staging vs KFRE 🧪 Glycemic management in CKD

🪶 Nephrology-specific traps

Euglycemic DKA

Relative insulinopenia plus SGLT2i is the classic setup. At HbA1c above 10% with catabolic features, establish insulin before or alongside the SGLT2i.

eGFR floors

SGLT2i initiation down to eGFR 20 with continuation thereafter. Metformin contraindicated below 30. Finerenone requires potassium surveillance. GLP-1 RA dosing is not eGFR-adjusted.

Cardiorenal indication is not glycemic control

SGLT2i retains cardiorenal benefit to eGFR 20 but is not a glucose-lowering agent at G4. Do not let the cardiorenal indication substitute for glycemic management.

Dialysis (stage 4b)

HbA1c has low reliability, pre-HF biomarker cut points are uninterpretable, and PREVENT is not applicable. Three of the framework's instruments go dark at once.

Where implementation will actually fail. The guideline's structural recommendations — a named CKM coordination point person, routine social-determinants screening, and selected screening for pre-HF, MASLD and OSA — are the operational core. They are also the parts most health systems will not build.

🔍 Source and verification

Primary source: the 2026 AHA/ACC/ADA/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome (Circulation. 2026;154(4):e50–e158, PMID 42263157), published Free Access and read in full for these pages. Glycemic triggers are from the ADA Standards of Care in Diabetes — 2026, Section 9 (PMID 41358900), read in full via PubMed Central. Kidney staging and glycemic targets in CKD are from KDIGO 2024 and KDIGO 2022 (PMID 36272764), the latter verified against its peer-reviewed synopsis (PMID 36623286).

Every numeric threshold on this page was checked against the source text. Figures that could not be confirmed in a primary source were removed rather than published with a caveat — including a set of pre-HF biomarker cut points that circulate in secondary summaries but appear nowhere in the guideline.

📚 Key references

Ndumele CE, Rodriguez F, Dixon DL, et al. 2026 AHA/ACC/ADA/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome. Circulation. 2026;154(4):e50–e158. PMID 42263157.
Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the AHA. Circulation. 2023;148(20):1606–1635. PMID 37807924.
Khan SS, Matsushita K, Sang Y, et al. Development and validation of the AHA's PREVENT equations. Circulation. 2024;149(6):430–449. PMID 37947085.
Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on CKD outcomes in type 2 diabetes (FIDELIO-DKD). N Engl J Med. 2020;383(23):2219–2229. PMID 33264825.
Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on CKD in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109–121. PMID 38785209.

❤️ CKM Syndrome